Among 153 migraine patients who failed prior CGRP monoclonal antibody therapy, switching to fremanezumab achieved ≥50% reduction in monthly migraine days in 42.8% — supporting switching between CGRP-pathway antibodies.
42.8% response rate after switchingMigraine patients who failed prior CGRP mAb achieved ≥50% migraine day reduction with fremanezumab
What the researchers found
42.8% of migraine patients who failed prior CGRP mAb therapy achieved ≥50% reduction in monthly migraine days after switching to fremanezumab in the real-world Finesse Study.
Why it matters
Many migraine patients are told they've 'failed CGRP therapy' after one antibody doesn't work. This data shows that switching between receptor-targeting and ligand-targeting antibodies can rescue nearly half of these patients — expanding treatment options significantly.
The numbers in context
Subgroup analysis from the Finesse Study; patients who switched from erenumab, galcanezumab, or eptinezumab to fremanezumab.
How the study worked
Subgroup analysis of the Finesse Study, a real-world effectiveness study of fremanezumab. 153 patients with documented prior failure of another CGRP-pathway monoclonal antibody were analyzed.
Who was studied
Migraine patients who switched to fremanezumab from another CGRP mAb
What this study cannot tell us
Subgroup analysis — not a dedicated switching trial. Open-label, non-randomized design. 153 patients is moderate for subgroup analysis. Response definition (≥50% reduction) may miss meaningful partial responders. Reasons for prior mAb failure varied.
How to read the evidence
Moderate evidence — real-world subgroup analysis with meaningful clinical results, but non-randomized open-label design.
When this study was published
Published in 2024. Addresses the growing clinical question of CGRP antibody switching.
The bigger picture
The concept of 'within-class switching' for CGRP antibodies is clinically important because insurers often deny coverage for a second CGRP antibody after the first fails. This data supports the biological rationale for switching and could influence coverage policies.
Questions still open
- Does switching direction matter — is receptor-to-ligand switching more effective than ligand-to-ligand?
- How many patients who fail two CGRP mAbs would respond to a third?
- Should insurers mandate trying a different mechanism before declaring CGRP class failure?
Common questions
If one CGRP migraine drug didn't work for me, should I try another?
Why would a different CGRP antibody work when the first didn't?
Read the original research
Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway.
Dental and medical problems, 61(1), 9-11
Citation
Waliszewska-Prosół, Marta; Martelletti, Paolo. (2024). Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway.. Dental and medical problems, 61(1), 9-11. https://doi.org/10.17219/dmp/174706